A randomized competitive trial of Angiotensin II Receptor Blocker (ARB) for prevention of tumor recurrence in non-muscle invasive bladder cancer

INTERVENTION: ARB therapy for non‐muscle invasive bladder cancer Calcium channel blocker therapy for non‐muscle invasive bladder cancer CONDITION: Bladder cancer PRIMARY OUTCOME: 3‐year recurrence‐free survival rate SECONDARY OUTCOME: Safety; Quality of Life; Overall survival INCLUSION CRITERIA: 1. Pathological diagnosis ; urothelial carcinoma. 2. Patients who are initially diagnosed as non‐muscle invasive bladder cancer and treated completely by transurethral resection. 3. More than 20 years old at diagnosis. 4. Performance status (ECOG) of the cases should be 0 or 1. 5. Function of important organ should be sufficient. 6. Tolerable for internal use for ARB. 7. Agreement form for this study should be obtained from the patients. 8. Inspection value standard 3000/mm3 <= WBC < 12,000/mm3 Neutrophile ;1,500/mm3<= Platelet ;100,000/mm3<= sGOT/sGPT ; Within twice of normal range in respective institutes. sT‐bilirubin; <3mg/dl Hb; =>9.0g/dls Creatinin; <2.0mg/dl